Publications by authors named "Atefeh Javidialsaadi"
JAMA Cardiol
September 2024
Article Synopsis
- - Patients with heart failure and preserved ejection fraction (HFpEF) who have an ejection fraction of 60% or higher have limited treatment options, making the study of new treatments important.
- - The EMBARK-HFpEF trial tested a drug called mavacamten on 30 patients with symptomatic HFpEF over 26 weeks, measuring outcomes such as NTproBNP and troponin levels to evaluate efficacy and safety.
- - Results showed significant reductions in NTproBNP and troponin levels, indicating potential benefits of mavacamten for these patients, although biomarker levels returned toward baseline after the drug was stopped.
